Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Recruiting
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
Who can join
Ages 18 to 89 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients 18-89 years of age * admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA * eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well) Exclusion Criteria: * diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%) * prescribed anticoagulation prior to stroke * treated with intravenous thrombolysis * treated with mechanical thrombectomy * missing NIH Stroke Scale score
About the study
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
What is being tested
- CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy) (genetic)
Sponsor: University of Alabama at Birmingham · Participants: 200 · Started: Apr 9, 2025
Contact the study team
- Ekaterina Bakradze, MD · Phone: 205-975-8569
- Nita Limdi, PharmD, PhD · Phone: 205-934-4385
Official record on ClinicalTrials.gov — NCT06943586
Locations in the U.S.
| Alabama | University of Alabama at Birmingham, Birmingham |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.